

Amendments to the Claims:

This listing of claims will replace all prior versions, and listings, of the claims in the application:

Listing of Claims:

Claim 1 (currently amended): A pharmaceutical formulation ~~for the prophylaxis or therapy of papillomavirus tumours, which comprises~~ comprising
a peptide of at least about 127 amino acids of a papillomavirus L2 protein, or a mixture of therapeutically effective fragments of papillomavirus L2 protein, wherein each of said fragments comprises at least about 127 amino acids of the papillomavirus L2 protein, wherein administration of the peptide to a subject infected with a papillomavirus results in the production of an immune response to the papillomavirus,
~~papillomavirus L2 protein and prophylactically or therapeutically effective fragment thereof~~ in admixture with a pharmaceutically acceptable carrier.

Claim 2 (previously presented): A formulation according to claim 1 wherein the L2 protein is a bovine papillomavirus BPV-2 protein or fragment thereof.

Claim 3 (currently amended): A formulation according to claim 2 wherein the ~~L2 protein fragment~~ peptide comprises substantially amino acids 90 to 467 of SEQ ID NO: 2.

Claim 4 (previously presented): A formulation according to claim 1 wherein the L2 protein is a bovine papillomavirus BPV-4 protein or fragment thereof.

Claim 5 (previously presented): A formulation according to claim 1 in the form of an injectable formulation, wherein the carrier is a pharmaceutically acceptable injection vehicle.

Claim 6 (previously presented): A formulation according to claim 5 which further comprises an adjuvant.

Claim 7 (currently amended): A formulation according to claim 1 wherein the papillomavirus L2 protein or therapeutically effective fragment thereof is present in the form of a fusion protein with a different co-protein.

Claim 8 (currently amended): A formulation according to claim 7 wherein the co-protein ~~in the L2 fusion protein~~ is beta-galactosidase.

Claim 9 (currently amended): A formulation ~~ae-cording~~ according to claim 7 wherein the co-protein is glutathione S-transferase (GST).

Claim 10 (currently amended): A formulation according to claim 1 which further comprises papillomavirus E7 protein or ~~effective~~ or a therapeutically effective fragment thereof.

Claim 11 (previously presented): A formulation according to claim 1 wherein the L2 protein or ~~fragment thereof~~ peptide is produced by recombinant DNA techniques.

Claim 12 (previously presented): A transformed bacterial cell producing recombinant L2 protein or therapeutically effective fragment thereof.

Claims 13-15 (canceled).

Claim 16 (new). The formulation according to claim 1, wherein the peptide comprises amino acids 11 to 201 of SEQ ID NO: 2.

Claim 17 (new). The method according to claim 4, wherein the peptide comprises amino acids 203 to 329 of SEQ ID NO: 2.

Claim 18 (new). The method according to claim 4, wherein the peptide comprises amino acids 330 to 525 of SEQ ID NO: 2.